A new point of care blood testing device is being introduced into frontline NHS services after an evaluation at three hospitals showed that it reduced A&E waiting times and helped clinicians make quicker decisions and get it right first time.
The Oxford AHSN study found the device speeded up antibiotic prescribing decisions in three-quarters of cases involving common childhood illnesses such as fever and abdominal pain. It also improved the quality of care by enabling potentially life-threatening conditions such as sepsis to be identified earlier.
The study found that the Horiba Medical automated analyser delivered lab quality results on average three hours quicker than traditional lab tests. It also saved the NHS money – independent economic analysis identified potential combined net annual savings of more than £60,000 across the three hospitals largely through more efficient use of clinicians’ time.
Wider application has been demonstrated and NHS organisations are now investing in the devices. They are contributing to streamlining diagnostic pathways in the community for frail elderly patients, enabling more care closer to home and easing pressure on A&E departments. Wider use of the automated analyser is being investigated relating to paediatric appendicitis.
In emergency medicine blood tests are carried out when diagnosis is unclear to help with clinical decision-making around admission. A C-Reactive Protein (CRP) assay is a commonly used blood test, particularly as a potential proxy indicator for bacterial infection, often alongside a full blood count (FBC). The test is normally performed in a hospital laboratory which takes about 60-90 minutes. However, the time from needle to result can be considerably longer – up to several hours.
CRP and FBC are commonly used in paediatric emergency care to assist clinical decision-making. CRP is also used as a proxy indicator for the presence or absence of bacterial infection. The Oxford AHSN chose to evaluate Horiba Medical’s Microsemi CRP point of care device because it is an automated analyzer uniquely capable of simultaneously measuring CRP and FBC, as well as offering the potential to speed up clinical decision-making, improve care and reduce NHS costs.
A unique automated haematology analyser (the Horiba Microsemi CRP) was evaluated for three months at three paediatric emergency departments. The AHSN set up protocols, arranged equipment loans, facilitated training and provided project management.
The aim was to establish whether the device led to quicker diagnosis of common paediatric conditions including fever, limpness and abdominal pain, improved patient flow, reduced waiting time by speeding up assessment and reduced unnecessary antibiotic prescribing.
The Horiba Medical automated analyser point of care blood testing device reduced A&E waiting times and helped clinicians make quicker decisions and get it right first time. It detects infection and inflammation within four minutes of a pinprick test enabling immediate treatment or referral.
As a result, antibiotic prescribing decisions were speeded up in three-quarters of cases involving common childhood illnesses such as fever and abdominal pain. Quality of care also improved with potentially life-threatening conditions such as sepsis identified earlier.
The device delivered lab quality results on average three hours quicker than traditional lab tests. In one emergency paediatric department an earlier decision could have been made in 75% of cases.
The study found that the device was an effective stratification tool identifying children needing specialist referral more quickly and could shorten the time to decision-making about antibiotic use. In one case a high CRP result prompted urgent registrar review and initiation of IV antibiotics. The child had pyelonephritis and use of the reduced the clinical decision-making time by 50 minutes.
It also saved the NHS money – independent economic analysis by the York Health Economics Consortium identified potential combined net annual savings of more than £60,000 across three hospitals largely through more efficient use of clinicians’ time. There are also potential savings from quicker treatment decisions when a delay could have adverse effects on the patient’s condition.
Reduced waiting time for test results also improves patient flow, particularly at peak times, assisting service redesign.
The device found wider application supporting community frailty assessment pathways.
The study findings have been fed into the national antimicrobial medicines review.
The Oxford AHSN supported business case development to introduce the devices on the NHS frontline.
The Oxford AHSN has an ongoing connection with Horiba Medical and both work with BIVDA, the in vitro diagnostics technologies industry body.
The Oxford AHSN shared the results of the evaluation both within and outside its region. Within the Oxford AHSN one trust has invested in the analysers and is using them to streamline existing diagnostic pathways in the community for frail elderly patients, enabling more care closer to home and easing pressure on A&E departments. Other trusts have also taken an interest. Wider use of the analyser is being investigated relating to paediatric appendicitis.